News Novartis' oral BTK drug moves the needle in CINDU Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.
News Novartis breaks ground on San Diego biomedical R&D site Novartis has started construction of a $1.1bn biomedical research centre in San Diego that will serve as the hub for its R&D operations.
Sales & Marketing Four reasons pharma is sweeping the Super Bowl despite FDA f... The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?
News Patent losses hit Novartis hard, but CEO has a plan Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.
News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News GSK reaches $2.2bn deal to buy food allergy biotech RAPT GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.